Clinical trial · Interventional
A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
NCT00262210CI-TRIAL-00000232completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\* AIMS OF THE STUDY 1. To test if steroid-free chemotherapeutic regimens decrease the risk of HBV reactivation and hepatitis development in HBsAg (+) carriers. 2. To compare the efficacy of steroid-free chemotherapeutic regimens with that of steroid-containing regimens in terms of lymphoma control. 3. To study the change of activity of HBV and other hepatotropic viruses during the course of chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide Epirubicin Etoposide Prednisolone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- We expect to enter 25 patients per year and finish accrual of patients within 4 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
* Inclusion Criteria: 1. Histologically proven NHL, and for which intensive chemotherapy is considered treatment-of-choice. 2. HBsAg-positive. 3. No previous chemotherapy and radiotherapy. 4. No concurrent radiotherapy. AGC ≧ 2,000/mm3, Platelet ≧ 100,000/mm3 of peripheral blood. 5. Total bilirubin ≦ 2.5 mg/dl. Alanine aminotransferase (SGPT) \< 200 I.U/L 6. Serum creatinine ≦1.5 mg/dl Blood urea nitrogen (BUN) ≦ 25 mg/dl 7. Objectively measurable or evaluable disease 8. Signed informed consent * Exclusion Criteria: 1. Age \> 75 years, or Age \< 15 years 2. Pregnant or breast-feeding women. 3. Patients with history of brain metastasis or CNS involvement. 4. Child's class B or C in patients with liver cirrhosis. 5. Impaired cardiac function with NYHA (New York Heart Association) classification ≧ GrII. 6. Concurrent glucocorticoids use (for other reasons). The conventional use of glucocorticoids for antiemetic purpose is also not allowed.
References
Publications (0)
Data not yet available
No reference posted for this study.